Review ArticleReviews

Asthma and Adherence to Inhaled Corticosteroids: Current Status and Future Perspectives

Camilla Boslev Bårnes and Charlotte Suppli Ulrik
Respiratory Care March 2015, 60 (3) 455-468; DOI: https://doi.org/10.4187/respcare.03200

References

  1. 1.↵
    1. Masoli M,
    2. Fabian D,
    3. Holt S,
    4. Beasley R
    , Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59(5):469–478.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Accordini S,
    2. Corsico AG,
    3. Braggion M,
    4. Gerbase MW,
    5. Gislason D,
    6. Gulsvik A,
    7. et al
    . The cost of persistent asthma in Europe: an international population-based study in adults. Int Arch Allergy Immunol 2013;160(1):93–101.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Backer V,
    2. Ulrik CS,
    3. Hansen KK,
    4. Laursen EM,
    5. Dirksen A,
    6. Bach-Mortensen N
    . Atopy and bronchial responsiveness in random population sample of 527 children and adolescents. Ann Allergy 1992;69(2):116–122.
    OpenUrlPubMed
  4. 4.↵
    1. Eder W,
    2. Ege MJ,
    3. von Mutius E
    . The asthma epidemic. N Engl J Med 2006;355(21):2226–2235.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Bateman ED,
    2. Hurd SS,
    3. Barnes PJ,
    4. Bousquet J,
    5. Drazen JM,
    6. FitzGerald M,
    7. et al
    . Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31(1):143–178.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Blais L,
    2. Suissa S,
    3. Boivin JF,
    4. Ernst P
    . First treatment with inhaled corticosteroids and the prevention of admissions to hospital for asthma. Thorax 1998;53(12):1025–1029.
    OpenUrlAbstract/FREE Full Text
  7. 7.
    1. Haahtela T,
    2. Järvinen M,
    3. Kava T,
    4. Kiviranta K,
    5. Koskinen S,
    6. Lehtonen K,
    7. et al
    . Comparison of a β2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991;325(6):388–392.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Pauwels RA,
    2. Pedersen S,
    3. Busse WW,
    4. Tan WC,
    5. Chen YZ,
    6. Ohlsson SV,
    7. et al
    . Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 2003;361(9363):1071–1076.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Barnes PJ,
    2. Woolcock AJ
    . Difficult asthma. Eur Respir J 1998;12(5):1209–1218.
    OpenUrlAbstract
  10. 10.↵
    1. Davidsen JR
    . Drug utilization and asthma control among young Danish adults with asthma. Analyses of trends and determinants. Dan Med J 2012;59(8):B4501.
    OpenUrlPubMed
  11. 11.↵
    1. Kandane-Rathnayake RK,
    2. Matheson MC,
    3. Simpson JA,
    4. Tang ML,
    5. Johns DP,
    6. Meszaros D,
    7. et al
    . Adherence to asthma management guidelines by middle-aged adults with current asthma. Thorax 2009;64(12):1025–1031.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Krishnan JA,
    2. Riekert KA,
    3. McCoy JV,
    4. Stewart DY,
    5. Schmidt S,
    6. Chanmugam A,
    7. et al
    . Corticosteroid use after hospital discharge among high-risk adults with asthma. Am J Respir Crit Care Med 2004;170(12):1281–1285.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Piecoro LT,
    2. Potoski M,
    3. Talbert JC,
    4. Doherty DE
    . Asthma prevalence, cost, and adherence with expert guidelines on the utilization of health care services and costs in a state Medicaid population. Health Serv Res 2001;36(2):357–371.
    OpenUrlPubMedWeb of Science
  14. 14.↵
    1. Tan R,
    2. Corren J
    . Omalizumab in the treatment of asthma. Expert Rev Respir Med 2011;5(6):747–756.
    OpenUrlPubMed
  15. 15.↵
    1. Liberati A,
    2. Altman DG,
    3. Tetzlaff J,
    4. Mulrow C,
    5. Gøtzsche PC,
    6. Ioannidis JP,
    7. et al
    . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009;62(10):e1–e34.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Moher D,
    2. Liberati A,
    3. Tetzlaff J,
    4. Altman DG
    , PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
    OpenUrlFREE Full Text
  17. 17.↵
    1. Williams LK,
    2. Joseph CL,
    3. Peterson EL,
    4. Wells K,
    5. Wang M,
    6. Chowdhry VK,
    7. et al
    . Patients with asthma who do not fill their inhaled corticosteroids: a study of primary nonadherence. J Allergy Clin Immunol 2007;120(5):1153–1159.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Williams LK,
    2. Peterson EL,
    3. Wells K,
    4. Ahmedani BK,
    5. Kumar R,
    6. Burchard EG,
    7. et al
    . Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol 2011;128(6):1185.e2–1191.e2.
    OpenUrl
  19. 19.↵
    1. Williams LK,
    2. Pladevall M,
    3. Xi H,
    4. Peterson EL,
    5. Joseph C,
    6. Lafata JE,
    7. et al
    . Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol 2004;114(6):1288–1293.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. Murphy AC,
    2. Proeschal A,
    3. Brightling CE,
    4. Wardlaw AJ,
    5. Pavord I,
    6. Bradding P,
    7. Green RH
    . The relationship between clinical outcomes and medication adherence in difficult-to-control asthma. Thorax 2012;67(8):751–753.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Gamble J,
    2. Stevenson M,
    3. McClean E,
    4. Heaney LG
    . The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med 2009;180(9):817–822.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Bender BG,
    2. Pedan A,
    3. Varasteh LT
    . Adherence and persistence with fluticasone propionate/salmeterol combination therapy. J Allergy Clin Immunol 2006;118(4):899–904.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    1. Hwang EK,
    2. Jin HJ,
    3. Nam YH,
    4. Shin YS,
    5. Ye YM,
    6. Nahm DH,
    7. Park HS
    . The predictors of poorly controlled asthma in elderly. Allergy Asthma Immunol Res 2012;4(5):270–276.
    OpenUrlPubMed
  24. 24.↵
    1. Ulrik CS,
    2. Søes-Petersen U,
    3. Backer V,
    4. Lange P,
    5. Harving H,
    6. Plaschke P
    . Disease variability in asthma: how do the patients respond?–and why? J Asthma 2008;45(6):507–511.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Apter AJ,
    2. Reisine ST,
    3. Affleck G,
    4. Barrows E,
    5. ZuWallack RL
    . Adherence with twice-daily dosing of inhaled steroids. Socioeconomic and health-belief differences. Am J Respir Crit Care Med 1998;157(6 Pt 1):1810–1817.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Suissa S,
    2. Ernst P,
    3. Kezouh A
    . Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax 2002;57(10):880–884.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Suissa S,
    2. Ernst P,
    3. Benayoun S,
    4. Baltzan M,
    5. Cai B
    . Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000;343(5):332–336.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    1. Bateman ED,
    2. Boushey HA,
    3. Bousquet J,
    4. Busse WW,
    5. Clark TJ,
    6. Pauwels RA,
    7. et al
    . Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med 2004;170(8):836–844.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Juniper EF,
    2. O'Byrne PM,
    3. Guyatt GH,
    4. Ferrie PJ,
    5. King DR
    . Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;14(4):902–907.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. van Dixhoorn J,
    2. Duivenvoorden HJ
    . Efficacy of Nijmegen Questionnaire in recognition of the hyperventilation syndrome. J Psychosom Res 1985;29(2):199–206.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    1. Snaith RP
    . The Hospital Anxiety And Depression Scale. Health Qual Life Outcomes 2003;1:29.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Jin Y,
    2. Hu D,
    3. Peterson EL,
    4. Eng C,
    5. Levin AM,
    6. Wells K,
    7. et al
    . Dual-specificity phosphatase 1 as a pharmacogenetic modifier of inhaled steroid response among asthmatic patients. J Allergy Clin Immunol 2010;126(3):618.e2–625.e2.
    OpenUrl
  33. 33.↵
    1. Bateman ED,
    2. Frith LF,
    3. Braunstein GL
    . Achieving guideline-based asthma control: does the patient benefit? Eur Respir J 2002;20(3):588–595.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Rasmussen LM,
    2. Phanareth K,
    3. Nolte H,
    4. Backer V
    . Internet-based monitoring of asthma: a long-term, randomized clinical study of 300 asthmatic subjects. J Allergy Clin Immunol 2005;115(6):1137–1142.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    1. Araújo L,
    2. Jacinto T,
    3. Moreira A,
    4. Castel-Branco MG,
    5. Delgado L,
    6. Costa-Pereira A,
    7. Fonseca J
    . Clinical efficacy of web-based versus standard asthma self-management. J Invest Allergog Clin Immunol 2012;22(1):28–34.
    OpenUrl
  36. 36.↵
    1. Vollmer WM,
    2. Feldstein A,
    3. Smith DH,
    4. Dubanoski JP,
    5. Waterbury A,
    6. Schneider JL,
    7. et al
    . Use of health information technology to improve medication adherence. Am J Manag Care 2011;17(12 Spec No):SP79–SP87.
    OpenUrlPubMed
  37. 37.↵
    1. Wilson SR,
    2. Strub P,
    3. Buist AS,
    4. Knowles SB,
    5. Lavori PW,
    6. Lapidus J,
    7. et al
    . Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am J Respir Crit Care Med 2010;181(6):566–577.
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    1. Clark NM,
    2. Ko YA,
    3. Gong ZM,
    4. Johnson TR
    . Outcomes associated with a negotiated asthma treatment plan. Chron Respir Dis 2012;9(3):175–182.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Gamble J,
    2. Stevenson M,
    3. Heaney LG
    . A study of a multi-level intervention to improve non-adherence in difficult to control asthma. Respir Med 2011;105(9):1308–1315.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Ulrik CS,
    2. Claudius BK,
    3. Tamm M,
    4. Harving H,
    5. Siersted HC,
    6. Backer V,
    7. et al
    . Effect of asthma compliance enhancement training on asthma control in patients on combination therapy with salmeterol/fluticasone propionate: a randomised controlled trial. Clin Respir J 2009;3(3):161–168.
    OpenUrlPubMed
  41. 41.↵
    1. Winder JA,
    2. Nash K,
    3. Brunn JW
    . Validation of a life quality (LQ) test for asthma. Ann Allergy Asthma Immunol 2000;85(6 Pt 1):467–472.
    OpenUrlPubMed
  42. 42.↵
    1. Dweik RA,
    2. Boggs PB,
    3. Erzurum SC,
    4. Irvin CG,
    5. Leigh MW,
    6. Lundberg JO,
    7. et al
    . An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011;184(5):602–615.
    OpenUrlCrossRefPubMedWeb of Science
  43. 43.↵
    1. Emkey RD,
    2. Ettinger M
    . Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am J Med 2006;119(4 Suppl 1):S18–S24.
    OpenUrlCrossRefPubMed
  44. 44.
    1. Eisen SA,
    2. Miller DK,
    3. Woodward RS,
    4. Spitznagel E,
    5. Przybeck TR
    . The effect of prescribed daily dose frequency on patient medication compliance. Arch Int Med 1990;150(9):1881–1884.
    OpenUrlCrossRefPubMedWeb of Science
  45. 45.↵
    1. Glynn L,
    2. Fahey T
    . Cardiovascular medication: improving adherence. Clin Evid 2009;0220.
  46. 46.↵
    1. Price D,
    2. Robertson A,
    3. Bullen K,
    4. Rand C,
    5. Horne R,
    6. Staudinger H
    . Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm Med 2010;10:1.
    OpenUrlCrossRefPubMed
  47. 47.↵
    1. Wells KE,
    2. Peterson EL,
    3. Ahmedani BK,
    4. Williams LK
    . Real-world effects of once vs greater daily inhaled corticosteroid dosing on medication adherence. Ann Allergy Asthma Immunol 2013;111(3):216–220.
    OpenUrlCrossRefPubMedWeb of Science
  48. 48.↵
    1. Boulet LP,
    2. Vervloet D,
    3. Magar Y,
    4. Foster JM
    . Adherence: the goal to control asthma. Clin Chest Med 2012;33(3):405–417.
    OpenUrlCrossRefPubMedWeb of Science
  49. 49.↵
    1. Apter AJ,
    2. Wan F,
    3. Reisine S,
    4. Bender B,
    5. Rand C,
    6. Bogen DK,
    7. et al
    . The association of health literacy with adherence and outcomes in moderate-severe asthma. J Allergy Clin Immunol 2013;132(2):321–327.
    OpenUrlCrossRefWeb of Science
  50. 50.↵
    1. Sofianou A,
    2. Martynenko M,
    3. Wolf MS,
    4. Wisnivesky JP,
    5. Krauskopf K,
    6. Wilson EA,
    7. et al
    . Asthma beliefs are associated with medication adherence in older asthmatics. J Gen Intern Med 2013;28(1):67–73.
    OpenUrlPubMed
  51. 51.↵
    1. Cochrane MG,
    2. Bala MV,
    3. Downs KE,
    4. Mauskopf J,
    5. Ben-Joseph RH
    . Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. Chest 2000;117(2):542–550.
    OpenUrlCrossRefPubMedWeb of Science
  52. 52.↵
    1. Patel M,
    2. Perrin K,
    3. Pritchard A,
    4. Williams M,
    5. Wijesinghe M,
    6. Weatherall M,
    7. Beasley R
    . Accuracy of patient self-report as a measure of inhaled asthma medication use. Respirology 2013;18(3):546–552.
    OpenUrlPubMed
  53. 53.
    1. Rand CS,
    2. Wise RA,
    3. Nides M,
    4. Simmons MS,
    5. Bleecker ER,
    6. Kusek JW,
    7. et al
    . Metered-dose inhaler adherence in a clinical trial. Am Rev Respir Dis 1992;146(6):1559–1564.
    OpenUrlPubMedWeb of Science
  54. 54.↵
    1. Braunstein GL,
    2. Trinquet G,
    3. Harper AE
    . Compliance with nedocromil sodium and a nedocromil sodium/salbutamol combination. Compliance Working Group. Eur Respir J 1996;9(5):893–898.
    OpenUrlAbstract/FREE Full Text
  55. 55.↵
    1. Clatworthy J,
    2. Price D,
    3. Ryan D,
    4. Haughney J,
    5. Horne R
    . The value of self-report assessment of adherence, rhinitis and smoking in relation to asthma control. Prim Care Respir J 2009;18(4):300–305.
    OpenUrlCrossRefPubMed
  56. 56.↵
    1. Clerisme-Beaty EM,
    2. Bartlett SJ,
    3. Teague WG,
    4. Lima J,
    5. Irvin CG,
    6. Cohen R,
    7. et al
    . The Madison Avenue effect: how drug presentation style influences adherence and outcome in patients with asthma. J Allergy Clin Immunol 2011;127(2):406–411.
    OpenUrlPubMed
  57. 57.↵
    1. Lasmar L,
    2. Camargos P,
    3. Champs NS,
    4. Fonseca MT,
    5. Fontes MJ,
    6. Ibiapina C,
    7. et al
    . Adherence rate to inhaled corticosteroids and their impact on asthma control. Allergy 2009;64(5):784–789.
    OpenUrlCrossRefPubMedWeb of Science
  58. 58.↵
    1. Schroeder K,
    2. Fahey T,
    3. Ebrahim S,
    4. Peters TJ
    . Adherence to long-term therapies: recent WHO report provides some answers but poses even more questions. J Clin Epidemiol 2004;57(1):2–3.
    OpenUrlCrossRefPubMedWeb of Science
  59. 59.↵
    1. Rand CS,
    2. Nides M,
    3. Cowles MK,
    4. Wise RA,
    5. Connett J
    . Long-term metered-dose inhaler adherence in a clinical trial. The Lung Health Study Research Group. Am J Respir Crit Care Med 1995;152(2):580–588.
    OpenUrlPubMedWeb of Science
  60. 60.↵
    1. Bousquet J,
    2. Mantzouranis E,
    3. Cruz AA,
    4. Aït-Khaled N,
    5. Baena-Cagnani CE,
    6. Bleecker ER,
    7. et al
    . Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010;126(5):926–938.
    OpenUrlCrossRefPubMedWeb of Science
  61. 61.↵
    1. Neffen H,
    2. Fritscher C,
    3. Schacht FC,
    4. Levy G,
    5. Chiarella P,
    6. Soriano JB,
    7. et al
    . Asthma control in Latin America: the Asthma Insights and Reality in Latin America (AIRLA) survey. Rev Panam Salud Publica 2005;17(3):191–197.
    OpenUrlPubMedWeb of Science
  62. 62.↵
    1. Patel M,
    2. Pilcher J,
    3. Chan A,
    4. Perrin K,
    5. Black P,
    6. Beasley R
    . Six-month in vitro validation of a metered-dose inhaler electronic monitoring device: implications for asthma clinical trial use. J Allergy Clin Immunol 2012;130(6):1420–1422.
    OpenUrlPubMed
  63. 63.↵
    1. Patel M,
    2. Pilcher J,
    3. Travers J,
    4. Perrin K,
    5. Shaw D,
    6. Black P,
    7. et al
    . Use of metered-dose inhaler electronic monitoring in a real-world asthma randomized controlled trial. J Allergy Clin Immunol Pract 2013;1(1):83–91.
    OpenUrlCrossRefPubMed
  64. 64.↵
    1. Van Sickle D,
    2. Magzamen S,
    3. Truelove S,
    4. Morrison T
    . Remote monitoring of inhaled bronchodilator use and weekly feedback about asthma management: an open-group, short-term pilot study of the impact on asthma control. PLoS ONE 2013;8(2):e55335.
    OpenUrlPubMed
  65. 65.↵
    1. Vasbinder EC,
    2. Janssens HM,
    3. Rutten-van Molken MP,
    4. van Dijk L,
    5. de Winter BC,
    6. de Groot RC,
    7. et al
    . e-Monitoring of Asthma Therapy to Improve Compliance in children using a real-time medication monitoring system (RTMM): the e-MATIC study protocol. BMC Med Informatics Decision Making 2013;13:38.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Related Articles

Cited By...

Keywords